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Differential Cross-Regulation of the Human Chemokine Receptors CXCR1 and
CXCR2. Evidence for Time-Dependent Signal Generation
Abstract
Neutrophils and transfected RBL-2H3 cells were used to investigate the mechanism of cross-regulation of
the human interleukin-8 (IL-8) receptors CXCR1 and CXCR2 by chemoattractants. In neutrophils, Ca2+
mobilization by the CXCR2-specific chemokine, growth-related oncogene α (Groα), was desensitized by
prior exposure to the chemoattractants N-formylated peptides (fMLP) or a complement cleavage product
(C5a). In contrast, growth-related oncogene α did not desensitize the latter receptors. To investigate this
phenomenon, CXCR2 was stably expressed in RBL-2H3 cells and mediated phosphoinositide hydrolysis,
Ca2+ mobilization, chemotaxis, and secretion. In cells co-expressing CXCR2 and receptors for either C5a
(C5aR) or fMLP (FR), CXCR2 was cross-phosphorylated and cross-desensitized by C5a and fMLP.
However, neither C5aR nor FR was cross-phosphorylated or cross-desensitized by CXCR2 activation,
although CXCR1 did mediate this process. Receptor internalization induced by IL-8 was more rapid and
occurred at lower doses with CXCR2 than CXCR1, although both receptors mediated equipotent
chemotaxis and exocytosis in RBL. Truncation of the cytoplasmic tail of CXCR2 (331T) prolonged its
signaling relative to CXCR2, increased its resistance to internalization, and induced phospholipase D
activation. 331T was resistant to homologous phosphorylation and cross-phosphorylation but not crossdesensitization of its Ca2+ mobilization by fMLP or C5a, indicating an inhibitory site distal to receptor/G
protein coupling. In contrast to CXCR2, stimulation of 331T cross-desensitized Ca2+ mobilization by both
FR and C5aR. CXCR2 and the mutant 331T induced phospholipase C β3 phosphorylation to an extent
equivalent to that of CXCR1. Taken together, these results suggest that CXCR1 and CXCR2 bind IL-8 to
produce a group of equipotent responses, but their ability to generate other signals, including receptor
internalization, cross-desensitization, and phospholipase D activation, are very different. The latter
phenomena apparently require prolonged receptor activation, which in the case of CXCR2 is precluded by
rapid receptor phosphorylation and internalization. Thus, receptors coupling to identical G proteins may
trigger different cellular responses dependent on the length of their signaling time, which can be regulated
by receptor phosphorylation.
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Neutrophils and transfected RBL-2H3 cells were used
to investigate the mechanism of cross-regulation of the
human interleukin-8 (IL-8) receptors CXCR1 and CXCR2
by chemoattractants. In neutrophils, Ca21 mobilization
by the CXCR2-specific chemokine, growth-related oncogene a (Groa), was desensitized by prior exposure to the
chemoattractants N-formylated peptides (fMLP) or a
complement cleavage product (C5a). In contrast,
growth-related oncogene a did not desensitize the latter
receptors. To investigate this phenomenon, CXCR2 was
stably expressed in RBL-2H3 cells and mediated phosphoinositide hydrolysis, Ca21 mobilization, chemotaxis,
and secretion. In cells co-expressing CXCR2 and receptors for either C5a (C5aR) or fMLP (FR), CXCR2 was
cross-phosphorylated and cross-desensitized by C5a and
fMLP. However, neither C5aR nor FR was cross-phosphorylated or cross-desensitized by CXCR2 activation,
although CXCR1 did mediate this process. Receptor internalization induced by IL-8 was more rapid and occurred at lower doses with CXCR2 than CXCR1, although both receptors mediated equipotent chemotaxis
and exocytosis in RBL. Truncation of the cytoplasmic
tail of CXCR2 (331T) prolonged its signaling relative to
CXCR2, increased its resistance to internalization, and
induced phospholipase D activation. 331T was resistant
to homologous phosphorylation and cross-phosphorylation but not cross-desensitization of its Ca21 mobilization by fMLP or C5a, indicating an inhibitory site distal
to receptor/G protein coupling. In contrast to CXCR2,
stimulation of 331T cross-desensitized Ca21 mobilization by both FR and C5aR. CXCR2 and the mutant 331T
induced phospholipase C b3 phosphorylation to an extent equivalent to that of CXCR1. Taken together, these
results suggest that CXCR1 and CXCR2 bind IL-8 to produce a group of equipotent responses, but their ability
to generate other signals, including receptor internalization, cross-desensitization, and phospholipase D activation, are very different. The latter phenomena apparently require prolonged receptor activation, which in
the case of CXCR2 is precluded by rapid receptor phosphorylation and internalization. Thus, receptors coupling
to identical G proteins may trigger different cellular responses dependent on the length of their signaling time,
which can be regulated by receptor phosphorylation.
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Interleukin-8 (IL-8)1 is a key mediator of immunological
reactions in inflammatory disorders such as respiratory distress syndrome, idiopathic pulmonary fibrosis, rheumatoid arthritis, and asthma (1). IL-8 is the best characterized member
of the CXC subfamily of chemokines, which includes neutrophil-activating peptide 2, interferon-inducible protein 10, stromal cell-derived factor, and growth-related oncogenes a, b, and
g (GROa, -b, and -g) (2). Leukocyte responses to IL-8 are
mediated via specific cell surface receptors for IL-8. Two subtypes of IL-8 receptors have been described in neutrophils,
IL-8RA (CXCR1) and IL-8RB (CXCR2) (3, 4). Like the chemoattractant receptors FR and C5aR, CXCR1 and CXCR2 couple to
a pertussis toxin (Ptx)-sensitive G protein to mediate leukocyte
functions (5). Both CXCR1 and CXCR2 stimulate PI hydrolysis,
intracellular Ca21 mobilization, chemotaxis, and exocytosis,
whereas only CXCR1 stimulation results in the activation of
PLD and the respiratory burst, indicating that the two receptors may play different physiological roles during inflammation
(2). This inherent difference between two receptors with shared
ligands allows the exploration of the molecular distinctions
that control the ability of these receptors to initiate specific
cellular activities.
Studies with neutrophils and transfected cell lines have demonstrated that CXCR1 and CXCR2 undergo homologous (agonistdependent) and heterologous (agonist-independent) phosphorylation and desensitization (6 –10). In addition, Ca21
mobilization studies in neutrophils have indicated that responses to IL-8 are desensitized by prior exposure to IL-8,
fMLP, or C5a and vice versa, a phenomenon described as “class
desensitization” (7, 11). To date, little is known about the
mechanism governing IL-8 receptor regulation and cross-regulation. Co-expression in RBL-2H3 cells of CXCR1 with FR,
C5aR, or PAFR showed that CXCR1 becomes phosphorylated
and desensitized by pretreatment of the cells with IL-8, fMLP,
or C5a (12, 13). Stimulation of CXCR1 by IL-8 also desensitized
Ca21 mobilization in response to FR, C5aR, and PAFR (12, 13).
Recent studies in this laboratory, using wild type and a phosphorylation-deficient mutant of CXCR1, have demonstrated
that cross-regulation of CXCR1-mediated Ca21 mobilization
can occur as a consequence of receptor phosphorylation or at a
site distal from receptor/G protein coupling, decreasing activation of PLC (14). Whether CXCR2, like CXCR1, cross-desensitizes responses to FR or C5aR remained to be addressed. More1
The abbreviations used are: IL-8, interleukin-8; fMLP, N-formylmethionylleucylphenylalanine; FR, fMLP receptor; C5a, a complement
cleavage product; C5aR, C5a receptor; CXCR1, IL-8 receptor A; CXCR2,
IL-8 receptor B; PAF, platelet-activating factor; PAFR, PAF receptor;
Ptx, pertussis toxin; PMA, phorbol 12-myristate 13-acetate; G protein,
GTP-regulatory protein; cpt-cAMP, 8-(4-chlorophenylthio)-adenosine
39-cyclic monophosphate; GROa, -b, and -g, growth-related oncogene a,
b, and g, respectively.
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over, little is known regarding the comparative activation or
regulation of these two receptors for IL-8. For this purpose,
neutrophils and RBL-2H3 cells stably co-expressing the wild
type or a cytoplasmic tail deletion mutant of CXCR2 with
receptors for either fMLP or C5a were used to study the mechanism(s) of CXCR2 regulation and cross-regulation. The results
presented here demonstrate that responses to CXCR2 can be
cross-regulated by either fMLP or C5a. In contrast to CXCR1,
CXCR2 did not cross-regulate responses to the other chemoattractant receptors. However, deletion of the cytoplasmic tail of
CXCR2 delayed its internalization and prolonged signal generation, thus disclosing the requirements for time-dependent activation in certain receptor-mediated signals.
EXPERIMENTAL PROCEDURES

Materials—[32P]Orthophosphate (8500 –9120 Ci/mmol), myo-[2-3H]inositol (24.4 Ci/mmol), and [g-32P]GTP (6000 Ci/mmol) were purchased
from NEN Life Science Products. 125I-IL-8 was obtained from Amersham Pharmacia Biotech. IL-8 (monocyte-derived) and GROa were
purchased from Genzyme. Geneticin (G418) and all tissue culture reagents were purchased from Life Technologies, Inc. Monoclonal 12CA5
antibody, protein G-agarose, and protease inhibitors were purchased
from Boehringer Mannheim. Anti-human IL-8RB (CXCR2) antibody
was purchased from Pharmigen. Polyclonal antibody against PLCb3
was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
fMLP, indo-1 acetoxymethyl ester, and pluronic acid were purchased
from Molecular Probes, Inc. (Eugene, OR). C5a and cpt-cAMP, phorbol
12-myristate 13-acetate (PMA), GDP, GTP, and ATP were purchased
from Sigma. All other reagents are from commercial sources. The cDNA
encoding the human CXCR2 was kindly provided by Drs B. Moser and
M. Baggiolini.
Isolation of Human Neutrophils—Neutrophil purification (;95%
PMNs) was carried out as described previously (7).
Construction of Epitope-tagged FR, C5aR, CXCR1, and PAFR—Nucleotides encoding a 9-amino acid hemagglutinin (HA) epitope sequence
(YPYDVPDYA) was inserted between the N-terminal initiator methionine and the second amino acid of each cDNA by polymerase chain
reaction as described previously (15).
Cell Culture and Transfection—RBL-2H3 cells were maintained as
monolayer cultures in Earle’s modified Eagle’s medium supplemented
with 15% fetal bovine serum, 2 mM glutamine, penicillin (100 units/ml),
and streptomycin (100 mg/ml) (15). RBL-2H3 cells (1 3 107 cells) were
transfected by electroporation with pcDNA3 containing the receptor
cDNAs (20 mg), and Geneticin-resistant cells were cloned into single cell
by fluorescence-activated cell sorting analysis.
Radioligand Binding Assays—RBL-2H3 cells were subcultured overnight in 24-well plates (0.5 3 106 cells/well) in growth medium. Cells
were then rinsed with Dulbecco’s modified Eagle’s medium supplemented with 20 mM HEPES, pH 7.4, and 10 mg/ml bovine serum
albumin and incubated on ice for 2– 4 h in the same medium (250 ml)
containing the radiolabeled ligand. Reactions were stopped with 1 ml of
ice-cold phosphate-buffered saline containing 10 mg/ml bovine serum
albumin and washed three times with the same buffer. Then cells were
lysed with 0.1 N NaOH (250 ml) and dried under vacuum, and bound
radioactivity was counted (9, 14). Nonspecific radioactivity bound was
determined in the presence of 300 nM unlabeled ligand.
GTPase Activity—Cells were treated with appropriate concentrations of stimulants, and membranes were prepared as already described
(9). GTPase activity using 10 –20 mg of membrane preparations were
carried out as described previously (9, 16).
Phosphoinositide Hydrolysis and Calcium Measurement—RBL-2H3
cells were subcultured overnight in 96-well culture plates (50,000 cells/
well) in inositol-free medium supplemented with 10% dialyzed fetal
bovine serum and 1 mCi/ml [3H]inositol. The generation of inositol
phosphates was determined as reported (15). For calcium mobilization,
cells (3 3 106) were removed, washed with HEPES-buffered saline, and
loaded with 1 mM indo-1 acetoxymethyl ester in the presence of 1 mM
pluronic acid for 30 min at room temperature. Then the cells were
washed and resuspended in 1.5 ml of buffer. Intracellular calcium
increase in the presence and absence of ligands was measured as
described (7, 15).
Chemotaxis—RBL-2H3 cells (50,000) were incubated at 37 °C with
different concentrations of IL-8. Chemotaxis was assessed in 48-well
microchemotaxis chambers, using polyvinylpyrrolidone-free 8-mm pore
size membranes. Migration was allowed to continue for 3 h at 37 °C in
humidified air containing 5% CO2. The membrane was removed, and
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the upper surface was washed with phosphate-buffered saline and
scraped, fixed, and stained. The results are represented as mean of
number of cells/well (14, 17). The results are representative of three
separate experiments.
Phospholipase D Activation Assay—Cells were subcultured in 24well plates (2.5 3 105 cells/well) overnight and labeled with [3H]myristic acid (2 mCi/well) in HEPES-buffered saline supplemented with 0.1%
bovine serum albumin for 90 min. Cells were then washed and stimulated with IL-8 (100 nM) for 5 min, and phosphatidylethanol formation
was measured as described previously (7, 13).
Phosphorylation of Receptors and PLCb3—Phosphorylation of receptors or PLCb3 was performed as described previously (9, 15, 18). RBL2H3 cells (2.5 3 106) expressing the receptors were incubated with
[32P]orthophosphate (150 mCi/dish) for 90 min. Then labeled cells were
stimulated with the indicated ligands for 5 min at 37 °C. Cell lysates
were immunoprecipitated with specific antibodies against the N terminus of CXCR2, the HA epitope tag (12CA5), or the PLCb3; analyzed by
SDS electrophoresis; and visualized by autoradiography.
Two-dimensional Peptide Mapping—PLCb3 phosphorylation was
carried out as described above, transferred to a nitrocellulose filter and
autoradiographed. Phosphoprotein bands corresponding to PLCb3 were
cut, washed, and digested with L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin, and two-dimensional peptide mapping
was performed as described (19, 20).
RESULTS

Cross-desensitization of CXCR2 in Neutrophils—To study
the cross-desensitization of CXCR2 by chemoattractants in
neutrophils, intracellular Ca21 mobilization elicited by GROa
was used as a measure of CXCR2 activation. As shown in Fig.
1, response to an EC100 dose of GROa (10 nM) was desensitized
by prior exposure of the cells to an EC100 dose of either C5a (10
nM) or fMLP (10 nM) but not PAF (10 nM). GROa pretreatment
did not affect intracellular Ca21 mobilization in response to
fMLP, C5a, or PAF.
Expression and Characterization of CXCR2 in RBL-2H3
Cells—To further study the cross-regulation of CXCR2, RBL2H3 cells stably expressing different combinations of receptors
were generated. Ligand binding studies of all receptors except
CXCR2 in RBL cells were previously determined and found to
be similar to native receptors in neutrophils (9, 13). CXCR2
bound both IL-8 (Kd 5 2.4 6 1.3 nM; Bmax 5 8460 6 232
receptors/cell) and GROa (Kd 5 1.9 6 0.9 nM; Bmax 5 7895 6
637 receptors/cell) with similar affinities. The Kd were similar
to that of CXCR2 expressed in 3ASubE cells (3.1 nM) (10), HEK
293 cells (4 nM) (21) or the native receptors in neutrophils
(;1–2 nM) (26). Upon IL-8 (Fig. 2) or GROa (data not shown)
activation, CXCR2 stimulated dose-dependent chemotaxis
(Fig. 2C), PI hydrolysis (Fig. 2A), secretion (Fig. 2D), and peak
of intracellular Ca21 mobilization (Fig. 2B). IL-8- (Fig. 2, A, B,
C, and D) and GROa- (data not shown) mediated CXCR2 responses were equipotent to those of CXCR1 (Fig. 2, A, B, C, and
D) in RBL-2H3 cells expressing similar number of receptors.
IL-8 induced a time- and dose-dependent internalization of
CXCR1 and CXCR2 (Fig. 2, E and F). In agreement with
previous reports (22, 23) CXCR2 internalized more quickly
(;95% versus ;50% for CXCR2 and CXCR1, respectively, after
30 min; Fig. 2E) and at lower doses than CXCR1 (Fig. 2F). The
rate of IL-8 induced CXCR2 internalization was similar to that
of GROa (data not shown). The dissociation rate constants
(Koff) were 1.319 6 0.21 and 1.275 6 0.17 min21 for IL-8 and
GROa, respectively).
Co-expression and Cross-desensitization of CXCR2 in RBL2H3 Cells—CXCR2 was co-expressed with receptors for either
C5a (CXCR2-C5aR) or fMLP (CXCR2-FR), and Ca21 mobilization was measured to study cross-desensitization among these
receptors. As in neutrophils, IL-8-induced Ca21 mobilization
was desensitized by pretreatment of the cells with a first dose
of either C5a (10 nM) or fMLP (100 nM) (Table I). Prior exposure
of the cells to a first dose of IL-8 had no effect on C5a or
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FIG. 1. Cross-desensitization of
CXCR2-mediated intracellular calcium mobilization in human neutrophils. Human neutrophils were loaded
with the calcium indicator indo-1 and exposed to a first EC100 dose (10 nM) of
GROa and either fMLP (A), C5a (B), or
PAF (C). Cells were rechallenged 3 min
later with a second dose of ligand as indicated. Traces are representative of three
experiments.

FIG. 2. Functional characterization of CXCR2 relative to CXCR1 expressed in RBL-2H3 cells. A, for the generation of [3H]inositol
phosphates, cells were cultured overnight in the presence of [3H]inositol (1 mC/ml). Cells were preincubated (10 min, 37 °C) with a HEPES-buffered
saline containing 10 mM LiCl in a total volume of 200 ml and stimulated with different concentrations of IL-8 for 10 min. [3H]Inositol phosphate
released was determined as described under “Experimental Procedures.” Data were corrected for basal and represented as total cpm. The
experiment was repeated four times with similar results. B, for intracellular calcium mobilization, RBL cells (3 3 106) were loaded with indo-1and IL-8- (10 nM) stimulated Ca21 mobilization was measured. Representative tracings of five experiments are shown. C, chemotactic response to
IL-8 was measured as described under “Experimental Procedures.” The results are representative of one of four experiments performed in
triplicate. D, for secretion, 10 ml of the supernatant for PI hydrolysis was removed, and b-hexosaminidase released was measured. Data are
represented as percentage of total b-hexosaminidase in the cells. The experiment was repeated four times with similar results. For IL-8-induced
internalization, RBL-2H3 cells (0.5 3 106 cells/well) expressing CXCR2 or CXCR1 were either treated with IL-8 (100 nM) at different times (E) or
with different concentrations of IL-8 for 30 min (F), washed, and assayed for 125I-IL-8 binding. The values are presented as percentage of total,
which is defined as the total amount of 125I-IL-8 bound to control (untreated) cells. The experiment was repeated twice with similar results.

fMLP-mediated Ca21 mobilization (Table I), although Ca21
response to a second dose of IL-8 was inhibited by ;90% (data
not shown). Similar results were obtained with GROa instead
of IL-8 (data not shown).
GTPase activity in membranes was measured to further
study the cross-desensitization of CXCR2. Pretreatment of
CXCR2-C5aR cells with IL-8 (100 nM), C5a (100 nM), or PMA
(100 nM) resulted in desensitization (50 – 60%) of IL-8-induced
GTPase activity in membranes (Fig. 3). Treatment of the cells

with either C5a or PMA, but not IL-8, resulted in a ;40%
desensitization of C5a-mediated GTPase activity.
Cross-phosphorylation of CXCR2—To determine whether
cross-desensitization of CXCR2 correlated with its cross-phosphorylation, 32P-labeled cells were stimulated with IL-8 (100
nM), C5a (100 nM), or fMLP (1 mM). The cell lysates were
immunoprecipitated first with a specific antibody directed
against the N terminus of CXCR2 and then with the 12CA5
antibody specific for the HA epitope tag expressed at the N

Cross-regulation of CXCR2
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TABLE I
Cross-desensitization of CXCR2-mediated Ca21 mobilization by C5a
and fMLP RBL-2H3 cells
RBL-2H3 cells (3 3 106 cells/assay) expressing CXCR2-C5aR or
CXCR2-FR were loaded with indo-1 and stimulated with IL-8 (10 nM),
C5a (10 nM), or fMLP (100 nM). Cells were rechallenged 3 min later with
a second dose of the indicated ligand, and peak intracellular Ca21
mobilization was determined. Data are the means 6 S.E. of three
different experiments.
Cells/treatment

CXCR2-C5aR
IL-8 3 C5a
C5a 3 IL-8

Peak Ca21 mobilization

Cross-desensitization

nM

%

450 6 27 3 494 6 36
484 6 32 3 187 6 10

CXCR2-FR
IL-8 3 fMLP 471 6 17 3 486 6 29
fMLP 3 IL-8 501 6 11 3 134 6 7

0
60

FIG. 4. Cross-phosphorylation of chemoattractant receptors.
P-Labeled RBL-2H3 cells (3 3 106/60-mm plate) expressing CXCR2
with either C5aR (CXCR2-C5aR) or FR (CXCR2-FR) were incubated for
5 min with or without stimulants as shown. Cells were lysed and
immunoprecipitated first with a CXCR2-specific antibody (AntiCXCR2) and second with 12CA5 antibody specific for the HA epitope
tag (Anti-HA) expressed at the amino terminus of C5aR and FR and
then analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. The results are from a representative experiment that was
repeated three times.
32

3
72

FIG. 3. Homologous desensitization and cross-desensitization
of CXCR2-mediated GTPase activity. Double transfected RBL-2H3
cells expressing CXCR2 and C5aR (CXCR2-C5aR) were treated with
IL-8 (100 nM), C5a (100 nM), or PMA (100 nM) for 5 min. Membranes
were prepared and assayed for agonist-stimulated GTP hydrolysis. The
data shown are the means of three different experiments performed in
triplicate. The data are presented as percentage of control, which is the
net maximal stimulation obtained with untreated cells. Data shown are
representative of one of three experiments performed in triplicate.

terminus of FR and C5aR (15). As shown in Fig. 4, CXCR2 was
homologously phosphorylated by IL-8 (A and B, lanes 2) and
cross-phosphorylated by C5a (A, lane 3) and fMLP (B, lane 3).
Two forms of CXCR2 were observed, a slow (;70-kDa) and a
fast migrating (;45-kDa) form. Similar results were obtained
with three different antibodies directed against the N terminus
of the CXCR2. C5aR (A, lane 6, ;42 kDa) and FR (B, lane 6,
;65 kDa) were homologously phosphorylated by their ligands.
No significant cross-phosphorylation of C5aR (A, lane 5) by IL-8
was observed. FR is resistant to that process (12, 13).
Dose-response of C5a-mediated cross-phosphorylation of
CXCR2 was also studied. Both forms of CXCR2 were crossphosphorylated to a similar extent by activation of C5aR (data
not shown). Half-maximal concentration was ;10 nM C5a, and
maximal cross-phosphorylation was obtained at ;33 nM.
Effect of Staurosporine on CXCR2 Cross-phosphorylation—
The involvement of protein kinase C on C5a-mediated crossphosphorylation of CXCR2 was studied. As shown in Fig. 5A,
IL-8-induced phosphorylation of CXCR2 was not affected by
staurosporine (lanes 3 and 4), whereas cross-phosphorylation
by C5a (lanes 5 and 6) and heterologous phosphorylation by
PMA (lanes 7 and 8) were markedly inhibited. As expected,
C5aR phosphorylation (Fig. 5B) by PMA was completely inhibited by staurosporine (lane 7 versus lane 8), whereas only the
fast form of C5a-mediated phosphorylation was blocked (lanes
5 and 6) (15).
Co-expression, Characterization, and Cross-desensitization of
331T in RBL-2H3 Cells—In order to assess the role of receptor
phosphorylation on CXCR2-mediated cellular responses, a
phosphorylation-deficient CXCR2 mutant, 331T, in which the

FIG. 5. Effect of staurosporine on cross-phosphorylation of
CXCR2. 32P-Labeled CXCR2-C5aR cells were incubated with and without staurosporine for 5 min and then stimulated with IL-8 (lanes 3 and
4), C5a (lanes 5 and 6), or PMA (lanes 7 and 8). Cells were lysed,
immunoprecipitated with anti-CXCR2 (A) and then 12CA5 (B) antibodies, electrophoresed into 10% SDS-polyacrylamide gel, and autoradiographed. Three other experiments yielded similar results.

carboxyl terminus has been truncated by placing a stop codon
at serine 331 (10) was co-transfected into RBL-2H3 cells with
either C5aR (331T-C5aR) or FR (331T-FR). Stable transfectants were generated, and single cell cloning was utilized to
isolate double transfectants. As was the case in 3ASubE cells,
the mutant 331T expressed in RBL cells bound 125I-IL-8 with a
Kd (3.8 6 1.7 nM), similar to that of CXCR2 (2.4 6 0.8 nM).
However, 331T was more active than CXCR2 in mediating
GTPase activity (Fig. 6A), PI hydrolysis (Fig. 6B), and b-hexosaminidase release (Fig. 6C). As reported previously (10),
331T mediated a sustained Ca21 mobilization (Fig. 6D) and
was resistant to IL-8-induced receptor internalization relative
to CXCR2 (5 versus 95% for 331T and CXCR2, respectively,
after 30 min of reactions) (Fig. 6E). IL-8 caused no PLD activity
in CXCR2 cells, whereas it showed an ;1.7-fold increase over
basal level in 331T cells (Fig. 6F).
331T was resistant to phosphorylation by IL-8 (Fig. 7, lanes
2 and 8) and cross-phosphorylation by either C5a (lane 3) or
fMLP (lane 9). C5aR (lane 6) and FR (lane 12) were homologously phosphorylated by C5a and fMLP, respectively. FR was
resistant to cross-phosphorylation (lane 11), whereas IL-8 stimulation of the receptor mutant 331T resulted in C5aR crossphosphorylation (lane 5).
Despite the absence of receptor phosphorylation, 331T-me-
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FIG. 6. Functional characteristics
of the phosphorylation deficient mutant of CXCR2, 331T. A, membranes
were prepared from RBL-2H3 cells expressing the CXCR2 mutant 331T and
wild type CXCR2 and assayed for timedependent IL-8-stimulated GTPase activity. The data shown are the means of
three different experiments performed in
triplicate. Phosphoinositide hydrolysis
(B) and b-hexosaminidase release (C)
were determined as described in the legend to Fig. 2. Data are represented as
-fold stimulation over basal level for PI
hydrolysis and percentage of total b-hexosaminidase release for secretion. Results
shown are representative of one of three
experiments performed in triplicate. D,
for intracellular calcium mobilization,
RBL cells (2.5 3 106) were loaded with
indo-1, and IL-8- (10 nM) stimulated Ca21
mobilization was measured. Representative tracings of three experiments are
shown. E, receptor internalization was
determined as described in the legend to
Fig. 2. F, for PLD activity, RBL-2H3 cells
expressing CXCR2 or 331T were labeled
with [3H]myristic acid and stimulated
with or without IL-8 (100 nM). Formation
of phosphatidylethanol (PtdEtOH) was
measured as described under “Experimental Procedures.” Data are represented as -fold increase over basal level
and are from one of two representative
experiments.

mobilization in response to 331T (71 and 62%, respectively).
Ptx pretreatment also inhibited Ca21 responses to both the
mutant 331T and the wild type CXCR2 (data not shown).
CXCR2 and 331T-mediated Phosphorylation of PLCb3—As
shown in Fig. 8, upon IL-8 stimulation both CXCR2 and the
mutant 331T induced phosphorylation of PLCb3 to an extent
similar to that of CXCR1 (;2-fold over basal) (14). Two-dimensional phosphopeptide mapping of the PLCb3 showed that
CXCR1, CXCR2, and 331T mediated phosphorylation of PLCb3
to the same peptides (data not shown).
DISCUSSION

FIG. 7. Cross-phosphorylation of 331T in RBL-2H3 cells. 32PLabeled RBL-2H3 cells expressing the CXCR2 mutant 331T and either
C5aR (331T-C5aR) or FR (331T-FR) were stimulated with IL-8 (100
nM), C5a (100 nM), or fMLP (1 mM). Cells were lysed, immunoprecipitated as described in the legend of Fig. 4, electrophoresed into 10%
SDS-polyacrylamide gel, and autoradiographed. The results are from a
representative experiment that was repeated three times.

diated Ca21 mobilization was cross-desensitized by pretreatment of the double transfectant cells with either C5a (53%) or
fMLP (55%) (Table II). However, in contrast to the wild type
CXCR2, pretreatment of cells with a first dose of IL-8 diminished Ca21 mobilization mediated by either C5aR or FR (Table
II). Both PMA and the cAMP analog cpt-cAMP inhibited Ca21

Regulation of chemoattractant receptors in leukocytes plays
a critical role in inflammatory processes and host defense (24).
Recent studies demonstrating myriad chemokines and chemokine receptors and a relationship between these and infectivity
of human immunodeficiency virus and other viruses have
spawned renewed interest in the regulation of chemoattractant
receptors. This laboratory has previously reported that motility
versus cytotoxic responses of leukocytes to chemoattractants
utilized sequential but distinct pathways (24 –26). The motility
responses were mediated by low doses of chemoattractant and
correlated with signals generated rapidly (peak 5 30 s). Cytotoxic responses required higher doses (;20 –50% higher) of
chemoattractant and were correlated with signals that peaked
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TABLE II
Cross-desensitization of Ca21 mobilization in cells expressing
331T-C5aR and 331T-FR
RBL-2H3 cells (3 3 106 cells/assay) expressing 331T-C5aR or
331T-FR were loaded with indo-1 and stimulated with either IL-8 (10
nM), C5a (10 nM), or fMLP (100 nM). Cells were rechallenged 3 min later
with a second dose of the indicated ligand, and the peak of intracellular
Ca21 mobilization was determined. Cells were also pretreated with
either PMA (100 nM) or cpt-cAMP (1 mM) for 5 min, and Ca21 mobilization in response to IL-8 was determined. Data are the means 6 S.E.
of three different experiments.
Cells/treatment

Peak Ca21 mobilization

Cross-desensitization

nM

%

331T-C5aR
IL-8 3 C5a
C5a 3 IL-8

581 6 23 3 324 6 9
636 6 11 3 274 6 6

49
53

331T-FR
IL-8 3 fMLP
fMLP 3 IL-8

517 6 3 3 305 6 19
493 6 12 3 233 6 15

38
55

0 3 150 6 16
0 3 196 6 4

71
62

PMA 3 IL-8
cpt-cAMP 3 IL-8

FIG. 8. CXCR2- and 331T-mediated PLCb3 phosphorylation.
RBL-2H3 cells expressing wild type CXCR2, the mutant 331T, or
CXCR1 were 32P-labeled and stimulated for 5 min with IL-8 (100 nM).
Cells were lysed, immunoprecipitated with anti-PLCb3 antibody, and
analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. The results are from a representative experiment that was repeated three times.

at ;2–5 min (24). It was speculated that the magnitude and
duration of the signals affected the activation of these pathways, but the mechanisms were poorly understood. The chemoattractants fMLP, C5a, and IL-8 equally mediate leukocyte
motility. However, despite the presence of two receptors for
IL-8 on the neutrophil surface, CXCR1, and CXCR2, cytotoxic
responses to IL-8 are lower in magnitude relative to fMLP and
C5a. FR, C5aR, and IL-8R cross-desensitized each other’s responses including chemotaxis, Ca21 mobilization, and arachidonic acid production (7, 12, 27). However, IL-8-mediated crossdesensitization of these receptors is lower in magnitude (20 –
30%) compared with fMLP and C5a (50 –70%) (7, 12). These
data suggest that while IL-8 receptors mediate leukocyte migration as well as FR and C5aR, their abilities to trigger the
cytotoxic and cross-desensitization signals are different. In the
present work, studies of CXCR2 and a phosphorylation-deficient mutant allowed better understanding of the time-dependent nature of receptor activation for cellular responses as well
as the relationship of these to receptor cross-desensitization.
Previous studies in transfected RBL-2H3 cells have shown
that CXCR1, upon IL-8 stimulation, cross-desensitized Ca21
mobilization in response to fMLP, C5a, and PAF to extents
similar to those observed in neutrophils (12, 13). Ca21 mobilization elicited in neutrophils by GROa, which is specific for
CXCR2, was used to address whether CXCR2 also generated a
cross-desensitizing signal. It was found that prior exposure of
neutrophils to either IL-8, fMLP, or C5a cross-desensitized
Ca21 mobilization elicited by a first dose of GROa. In contrast
to IL-8, however, GROa did not cross-desensitize Ca21 response to either IL-8, C5a, fMLP, or PAF. These results suggest
that the cross-desensitization effect observed in neutrophils
with IL-8 is due to CXCR1 activation and not CXCR2. Since
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IL-8 activates both receptors in neutrophils, double transfected
RBL-2H3 cells expressing CXCR2 and either FR or C5aR were
generated to further investigate the regulation of CXCR2. As
was the case in neutrophils, prior exposure of the cells to either
fMLP or C5a diminished the ability of CXCR2 to mediate Ca21
mobilization, but IL-8 or GROa pretreatment failed to attenuate responses to fMLP or C5a (Table I; data not shown). These
results mirrored the ones obtained in neutrophils with GROa
and further indicate that despite the ability of CXCR2 to bind
IL-8 and activate some cellular responses equipotent to
CXCR1, others are clearly different, and cross-regulation signals are diminished or absent in CXCR2 pathways.
Two mechanisms for cross-desensitization have been described: receptor/G protein uncoupling via receptor phosphorylation and modification of downstream effector(s) activity (7).
The peptide chemoattractants fMLP and C5a cross-desensitized CXCR2 as well as CXCR1 via both mechanisms. First,
CXCR2 was cross-phosphorylated upon C5aR and FR activation, resulting in inhibition by ;50% of CXCR2-mediated
GTPase activity (Figs. 3 and 4). Second, Ca21 mobilization in
response to the phosphorylation-deficient mutant receptor
331T was cross-desensitized by prior exposure of the cells to
either C5a or fMLP (Table II), indicating a susceptibility to
regulation at a site downstream for the receptor activation. In
contrast to CXCR1, CXCR2 failed to cross-phosphorylate C5aR
or cross-desensitize Ca21 mobilization to FR and C5aR (Fig. 4
and Table I). These results may be explained in two ways.
First, CXCR2, like PAFR, may couple to a G protein different
from FR and C5aR. However, PAFR responses are predominantly Ptx-insensitive (16), whereas CXCR2-mediated responses, as well as FR and C5aR, are entirely inhibited by Ptx
pretreatment. Second, CXCR2 undergoes rapid internalization
upon receptor activation (;95% CXCR2 versus ;40% CXCR1
in the first 3–5 min) (Fig. 2E). Thus, the duration of the responses to CXCR2 may not be sufficient to trigger the mechanism of cross-desensitization. This contention is supported by
the finding that activation of 331T, which is resistant to internalization (;5% after 30 min) and generates longer cellular
signals than the wild type CXCR2 (Fig. 6), cross-phosphorylated C5aR (Fig. 7) and cross-desensitized Ca21 mobilization in
response to both C5a and fMLP (Table II).
Recent studies from this laboratory (18, 28) and others (29)
have indicated that phosphorylation of PLCb upon receptor
activation may be responsible for the downstream inhibition of
receptor-mediated cellular responses. The peptide chemoattractant receptors, including CXCR2, couple to Ptx-sensitive G
proteins to activate PLCb via Gbg (30, 31). Of the four known
PLCb isozymes (PLCb1–PLCb4) only PLCb3 is expressed in
RBL-2H3 cells (18, 28). Thus, it could be reasoned that the
inability of CXCR2 to cross-desensitize responses to the other
chemoattractants reflects its inability to mediate PLCb3 phosphorylation. However, upon stimulation with an EC100 dose of
IL-8, the wild type CXCR2 and the mutant 331T mediated
PLCb3 phosphorylation to an extent similar to that of CXCR1,
;2-fold over basal level (Fig. 8) (14). Another explanation could
be that CXCR2 mediated PLCb3 phosphorylation at sites different from the other chemoattractant receptors. Two-dimensional peptide mapping, however, showed that both CXCR2
and C5aR mediated PLCb3 phosphorylation at the same domains (data not shown). In addition, 331T, which cross-desensitizes responses to FR and C5aR, mediated PLCb3 phosphorylation to the same extent as CXCR2 (Fig. 8). Taken together,
these results suggest that phosphorylation of PLCb may not be
the only mechanism of cross-desensitization at downstream
sites. Modification of other molecules such as the regulator of G
protein signaling or Gbg, which alter PLCb activity (32, 33),
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may play an important role in the cross-desensitization
process.
The observation that CXCR2 phosphorylation by either IL-8
(Fig. 5) or GROa (34) is resistant to inhibition by staurosporine
suggests that phosphorylation of the receptor is predominantly
by a GRK-dependent mechanism rather than through activation of second messenger-dependent kinases. IL-8-mediated
CXCR1 phosphorylation was partially inhibited by staurosporine, indicating both protein kinase C- and GRK-dependent
mechanisms (19). Both CXCR1 and CXCR2 undergo phosphorylation-mediated internalization and/or down-regulation upon
IL-8 stimulation. However, CXCR2 internalized more rapidly
and recovered more slowly than CXCR1 (;35% recovery of
CXCR2 versus 100% of CXCR2, after 90 min) (22, 23). Thus,
differential phosphorylation between CXCR1 and CXCR2 may
provide a molecular basis for their different rate of internalization/down-regulation and resensitization as well as generation
of a cross-desensitizing signal. Supporting that contention is
that the phosphorylation-deficient mutant 331T, which was
more resistant to internalization (;5% versus ;95% for 331T
and CXCR2, respectively, after 30 min; Fig. 6E) and generated
greater and longer signals than CXCR2 (i.e. GTPase activity,
PI hydrolysis, Ca21 mobilization, PLD activation) (Fig. 6),
cross-desensitizes Ca21 mobilization to FR and C5aR (Table
II). Taken together, these data may indicate that the ability to
generate a cross-desensitizing signal may depend on the extent
and length of activation of the receptor, which in the case of
CXCR2 is prevented by rapid phosphorylation of the carboxyl
terminus followed by receptor internalization. Additionally,
prolonged signal generation in 331T was accompanied by activation of PLD. In other studies, it was suggested that PLD
activation, which results in the delayed (peak in 2–5 min)
formation of large quantities of diacylglycerol, is correlated
with activation of the respiratory burst in neutrophils (34).
Thus, the nature of the signals triggered by chemoattractant
receptors appears to be governed by the length of receptor
activation.
In summary, these data indicate that despite the ability of
both CXCR1 and CXCR2 to initiate equivalent responses in
leukocytes (i.e. PI hydrolysis, Ca21 mobilization, PLCb3 phosphorylation, chemotaxis, and exocytosis) their ability to generate others including PLD activation, receptor cross-phosphorylation, and cross-desensitization are vastly different. These
results, together with the inability of CXCR2 to mediate PLD
activation and superoxide anion production in neutrophils,
support the hypothesis that the ability of chemoattractant receptors to mediate cytotoxic activation requires more prolonged
receptor activation than that required for motility-related responses. This distinction appears to be determined by phosphorylation sites on the receptors’ cytoplasmic tail, explaining the
previously noted hierarchy among chemoattractant receptors
to activate cytotoxic responses and receptor cross-regulation

(24). Overall, a complete understanding of the signaling properties of CXCR2 relative to CXCR1 will require specific mutation of the carboxyl terminus of the receptor.
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